Rigrodsky & Long, P.A. Investigates Immucor, Inc.'s Sale to TPG Capital for Shareholders

  • Do you own Immucor, Inc. common stock?
  • Did you purchase your shares prior to July 5, 2011?
  • Do you feel the Company's sale to TPG Capital is unfair?
  • Do you want to discuss your rights?

If the answer to these questions is "yes," please contact the deal lawyers at Rigrodsky & Long, P.A. ("R & L") today to schedule a FREE consultation. Just call us, or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.

Contact R & L today to be sure your best interests are being protected.

R & L is a national law firm with decades of combined legal experience. R & L is investigating potential claims against the board of directors of Immucor, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired and taken private by investment funds managed by TPG Capital in a transaction with a fully diluted equity value of $1.973 billion.

Click here to read the full press release.

Rigrodsky & Long, P.A. Investigates Immucor, Inc.'s Sale to TPG Capital for Shareholders

Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Immucor, Inc. (“Immucor” or the “Company”) (Nasdaq: BLUD) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired and taken private by investment funds managed by TPG Capital (“TPG”) in a transaction with a fully diluted equity value of $1.973 billion.

Under the proposed agreement, TPG will commence a tender offer for all of the outstanding shares of Immucor for $25.00 per share in cash no later than July 15, 2011.

The investigation concerns whether Immucor’s board of directors adequately shopped the Company to obtain the best price possible for Immucor’s shareholders before entering into the agreement with TPG.  Indeed, according to Yahoo! Finance, at least one analyst has set a $28.00 per share target for Immucor stock.

On April 6, 2011, Immucor issued its fiscal third quarter financial results wherein revenue increased 4% year-over-year and the Company’s former President and CEO, Gioacchino De Chirico, stated: “Given the global economic environment, our third quarter financial performance exceeded our expectations with year-over-year revenue growth and earnings expansion[.]”

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

R & L, with offices in Delaware and New York, litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Learn more about R&L:  Visit Our Website |  Our Firm  |  Our Practice Areas  |  FAQ's

Fill out the form below or call us toll-free at 888-969-4242, for a FREE no-obligation consultation.